Drugs / Recombinant Fowlpox-PSA(L155)/TRICOM
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00096551 | Nov 2004 → Dec 2009 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Fowlpox-PSA(L155)/TRICOM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00096551 ↗ |
| Known as | PROSTVAC-F/TRICOM | “Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)” NCT00096551 ↗ |
| Modality | Vaccine | “intratumoral vaccines of recombinant fowlpox vectors appear to be more potent in inducing antitumor effects” NCT00096551 ↗ |
| Route | Other | “The first two cohorts utilize a booster intraprostatic with dose escalation of rF-PSA(L155)/TRICOM.” NCT00096551 ↗ |